Ipca Laboratories Ltd. – Pioneering Global Pharmaceutical Solutions

Founded in 1949, Ipca Laboratories Ltd. is a Mumbai-based multinational pharmaceutical company renowned for its commitment to quality and innovation. With a presence in over 120 countries, Ipca specializes in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and finished formulations, catering to various therapeutic segments including anti-malarial, cardiovascular, anti-diabetic, and pain management.

Product Portfolio

Active Pharmaceutical Ingredients (APIs):

Ipca is a leading manufacturer of over 80 APIs, accounting for nearly 25% of its turnover. The company's backward integration strategy ensures supply chain reliability and cost competitiveness. Key APIs include:

• Atenolol (anti-hypertensive)

• Chloroquine Phosphate (anti-malarial)

• Hydroxychloroquine Sulphate (DMARD)

• Losartan (anti-hypertensive)

• Metoprolol Succinate (anti-hypertensive)

Formulations:

Ipca manufactures over 350 formulations across various dosage forms. In India, the company has a strong presence with products available at over 500,000 retail outlets. Internationally, Ipca markets around 75 brands across therapeutic categories such as:

• Cardiovascular

• Diabetes

• CNS

• Gastroenterology

• Pain management & Arthritis

• Anti-infectives

• Anthelmintics

• Ophthalmic

• Nutritional supplements

Global Presence

Ipca's global footprint spans over 120 countries across six continents. The company has established subsidiaries and marketing offices in regions including East and West Africa, Southeast Asia, CIS, Latin & Central America. Notably, Ipca has a strong presence in Russia, where products like Nemozole, Tenoric, and Normax are top brands in their respective categories.

Research & Development

Ipca invests approximately 8-10% of its annual revenue into research and development, focusing on innovation and the development of new therapeutic solutions. The company's R&D efforts have led to advancements in areas such as oncology, anti-infectives, and cardiovascular treatments.

Leadership

Dr. Anil Pareek serves as the President of Medical Affairs and Clinical Research at Ipca Laboratories. With a background in internal medicine and therapeutics, Dr. Pareek has contributed significantly to drug development, including the approval of hydroxychloroquine for type 2 diabetes management in India.